Medcaptain Medical Technology: passes HKEX hearing on 20 August, No.1 in infusion workstation for 8 consecutive years

NewTimeSpace News: On 21 August 2026, Medcaptain Medical Technology Co., Ltd. passed the listing hearing of the Hong Kong Stock Exchange on 20 August 2026, with Morgan Stanley and Huatai International acting as joint sponsors. The Company is a global medical device provider; as of 31 March 2026, its product portfolio comprised more than 60 life support products, 110 minimally invasive intervention products and 150 in vitro diagnostics products, with products having cumulatively reached more than 140 countries and regions worldwide; in China, its products have cumulatively covered more than 6,000 hospitals (including approximately 90% of Class 3A hospitals) across 31 provinces, municipalities and autonomous regions.

According to CIC, in the life support segment, the Company ranked first in China's infusion workstation market by sales for each year from 2018 to 2025, and first in China's enteral nutrition pump market for each year from 2021 to 2025, having launched the world's first remote infusion control system and China's first self-developed multi-channel infusion workstation; in the minimally invasive intervention segment, it ranked in the top three in China's digestive system minimally invasive intervention consumables market by sales for each year from 2022 to 2025; in the in vitro diagnostics segment, it launched the world's first fully automatic thromboelastography analyzer in 2021. The Company has established five R&D centers and six production centers in China and the UK, with local representative offices in strategic markets including the UK, the Netherlands, Turkey, India, Thailand, Mexico and Brazil.

Financially, the Company's revenue increased from RMB 1,313.3 million in 2023 to RMB 1,619.2 million in 2025, with gross margin improving from 49.6% in 2023 to 53.7% in 2025; it turned profitable in 2025 with a net profit of RMB 50.7 million; for the three months ended 31 March 2026, it recorded a net loss of RMB 2.5 million, mainly due to share-based payments of RMB 25.1 million under the share option scheme and listing expenses incurred.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.